Population pharmacodynamic modelling of aspirin- and ibuprofen-induced inhibition of platelet aggregation in healthy subjects

Clinical Pharmacokinetics

Volumn 47, Issue 2, 2008, Pages 129-137

  Hong, Ying ^a   Gengo, Fran M ^a,b   Rainka, Michelle M ^b   Bates, Vernice E ^b   Mager, Donald E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b DENT NEUROLOGIC INSTITUTE   (United States)

Author keywords

Aspirin, pharmacodynamics; Ibuprofen, pharmacodynamics; Pharmacodynamic modelling; Platelet aggregation antagonists, pharmacodynamics

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; COLLAGEN; CYCLOOXYGENASE 1; IBUPROFEN;

ACCURACY; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG MECHANISM; ENZYME DEGRADATION; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN EXPERIMENT; IMPEDANCE; MONTE CARLO METHOD; NONLINEAR SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION;

ADMINISTRATION, ORAL; ADULT; ARACHIDONIC ACID; ASPIRIN; COLLAGEN; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; HALF-LIFE; HUMANS; IBUPROFEN; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 38149012198     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847020-00006     Document Type: Article

References (24)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86
2. Funk CD, Funk LB, Kennedy ME, et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991; 5 (9): 2304-12
3. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72 (6): 1177-84
4. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69 (1): 180-6
5. Pathmakanthan S, O'Donovan DG, Sheehan KM, et al. Prospective evaluation of the utilization of aspirin and non-steroidal anti-inflammatory drugs in acute medical admissions. Ir Med J 1998; 91 (2): 58-60
6. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345 (25): 1809-17
7. Gengo FM, Rubin L, Robson M, et al. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol 2008; 48 (1): 117-22
8. Elwood PC, Beswick AD, Sharp DS, et al. Whole blood impedance platelet aggregometry and ischemic heart disease: the Caerphilly Collaborative Heart Disease Study. Arteriosclerosis 1990; 10 (6): 1032-6
9. Davies NM. Clinical pharmacokinetics of ibuprofen: the first 30 years. Clin Pharmacokinet 1998; 34 (2): 101-54
10. Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman's: the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1995
11. Suri A, Grundy BL, Derendorf H. Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. Int J Clin Pharmacol Ther 1997; 35 (1): 1-8
12. Benedek IH, Joshi AS, Pieniaszek HJ, et al. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 1995; 35 (12): 1181-6
13. SADAPT/MCPEM user's guide [computer program]. Version 1.53. Berkeley (CA). Available from URL: http://bmsr.usc.edu/Software/Adapt/sadapt.html [Accessed 2007 Dec 17]
14. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A 2001; 98 (25): 14583-8
15. Yamamoto K, Abe M, Katashima M, et al. Pharmacodynamic analysis of antiplatelet effect of aspirin in the literature-modeling based on inhibition of cyclooxygenase in the platelet and the vessel wall endothelium. Jpn J Hosp Pharm 1996; 22 (2): 133-41
16. Abelo A, Gabrielsson J, Holstein B, et al. Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and man. Eur J Pharm Sci 2001; 14 (4): 339-46
17. Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother 2005; 6 (12): 2027-45
18. McKenzie ME, Gurbel PA, Levine DJ, et al. Clinical utility of available methods for determining platelet function. Cardiology 1999; 92 (4): 240-7
19. Serebruany V, McKenzie M, Meister A, et al. Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT trial). Eur J Heart Fail 2002; 4 (4): 461-7
20. Sciulli MG, Renda G, Capone ML, et al. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. Clin Pharmacol Ther 2006; 80 (2): 115-25
21. Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the anti-platelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006; 80 (3): 264-74
22. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343 (21): 1520-8
23. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 45 (8): 1295-301
24. Gierse JK, Koboldt CM, Walker MC, et al. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 1999; 339 (Pt 3): 607-14